STVN

Stevanato GroupA

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-08-05

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+1

B+

Bull case

25%

Probability

Target price

$27.00

+37.4% vs current

Most likely

Base case

50%

Probability

Target price

$24.40

+24.2% vs current

B-

Bear case

25%

Probability

Target price

$17.00

-13.5% vs current

AI sentiment snapshot

Latest data as of 2026-08-05

AI commentary

The SEC 6-K Exhibit 99.1 was directly verified through a primary-source fetch and supports the Q2 results, guidance, operating drivers, and risks cited above. The latest available market snapshot was $20.12 versus the $19.65 August 4 anchor, a roughly 2.4% gain after the release. News tone is moderately positive, but social coverage, options data, short interest, employee sentiment, and validated post-print analyst revisions are unavailable. The deterministic packet shows very low evidence quality and high uncertainty, so this remains a cautious monitoring view rather than a high-conviction trade thesis.

RankAlpha Sentiment Codex - 2026-08-05

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-05eventQ2 2026 print and guidance updateMedium impact

Revenue rose 8% year over year to €302.0 million, adjusted EBITDA margin expanded 280 basis points to 26.0%, and management updated FY2026 guidance. No validated consensus comparison was available, so this is not characterized as a beat. [#SEC-6K-2026-08-04]

2026-09-30catalystCash conversion and Engineering execution riskHigh impact

Q2 free cash flow was negative €32.0 million with €360.3 million of net debt; Engineering revenue declined 2% and management remains cautious about elongated sales cycles and project phasing. [#SEC-6K-2026-08-04]

2026-12-31catalystDrug-delivery platform commercializationHigh impact

Management is advancing Alina and the newly introduced Deora platforms; the Q2 release cited EU approvals for a customer product incorporating Alina, while Deora targets diabetes and weight-management therapies. [#SEC-6K-2026-08-04] [#IR-2026-06-08]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-05 • Updated nightlySource: Internal modelMethodology